Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

The global vision care products market is projected to reach USD 103.7 billion by 2032, growing at a CAGR of 6.21%. This growth ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

TikTok influencers are mourning the impending shutdown of the popular Chinese-owned social media platform after the Supreme Court upheld a law to ban the application if it is not sold in the ...

These drops work with the eye's natural tears to help keep your contact lenses feeling fresh and comfortable all day Hydration Boost with Hyaluronate: Our moisturizing eye drops instantly ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"My patients appreciate being able to recycle their used eye health materials." Healthcare company keeps over 450,000 pounds ...